Products

What will AGI do for Benoxinate or oxybuprocaine?

This classification denotes an anesthetic agent with the molecular formula C17H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AXQ0JYM303, chemically known as benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7ci,8ci,9ci) but generally known as benoxinate, which bears US NIH Compound Identifier 4633. Benoxinate most often comes in base and hydrochloride forms. European Medicines Agency schedules Oxybuprocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09557MIG. The term OXYBUPROCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules benoxinate in its Anatomical Therapeutic Chemical (ATC) Classification. Benoxinate or oxybuprocaine bears US NLM identifiers UMLS ID C0053114 and NCI Concept Code C72176. SMILES: CCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N.

How AGI delivers it

Four ways AGI delivers for Benoxinate or oxybuprocaine

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Benoxinate or oxybuprocaine, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Benoxinate or oxybuprocaine, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Benoxinate or oxybuprocaine connects

measured by

  • Assay Puritymodel
  • Heavy Metal Contentmodel
  • Impurity Profilemodel
  • Melting Pointmodel
  • Residual Solventmodel